We are a pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing a broad portfolio of projects under development of therapeutic and diagnostic technologies to tackle unmet medical needs. Our principal office in Asia provides easy access to prosperous medical research resources and some of the worldâs most talented specialists and clinicians. We have established strong relationships and collaborations with leading academic institutions to propel therapeutic innovations. To date, Aptorum has obtained 12 exclusively licensed technologies in the areas of neurology, infectious diseases, gastroenterology, oncology, surgical robotics and natural health. Source
No articles found.
FibroGen, Inc. is a leading science-based biopharmaceutical company discovering an...
FibroGen, Inc. is a leading science-based bioph...
Alnylam is leading the translation of RNA interference (RNAi) into a whole new cla...
Alnylam is leading the translation of RNA inter...
SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused...
SELLAS Life Sciences Group, Inc. is a late-stag...
Collegium Pharmaceutical is a specialty pharmaceutical company committed to being ...
Collegium Pharmaceutical is a specialty pharmac...
Join the National Investor Network and get the latest information with your interests in mind.